Literature DB >> 3402178

Heparin sodium versus 0.9% sodium chloride injection for maintaining patency of indwelling intermittent infusion devices.

R A Hamilton1, J M Plis, C Clay, L Sylvan.   

Abstract

In a double-blind study, heparin sodium was compared with 0.9% sodium chloride injection for use in maintaining patency of indwelling devices for intermittent intravenous infusion. Adult patients who required intermittent intravenous devices were randomly assigned to receive 1 mL of a heparin sodium 100 units/mL flush solution or a 0.9% sodium chloride flush solution. Observations were recorded for each catheter, rather than for each patient. Patients were evaluated daily for the development of phlebitis. In the 160 patients for whom complete data on catheter patency were available, there were 307 observations (170 for the heparin group and 137 for the sodium chloride group). No significant difference in the duration of catheter patency or incidence of phlebitis was observed between the groups. A difference in the incidence of phlebitis could not be excluded with confidence, but inasmuch as there was no effect on duration of catheter patency, the clinical importance of this superficial venous phlebitis is questionable. The duration of patency was significantly greater in men than in women. The use of penicillins, cephalosporins, or clindamycin, alone or in combination, was significantly associated with the development of phlebitis for both treatment groups. No other factors were found to correlate with either the duration of catheter patency or incidence of phlebitis. The results of this study indicate that heparin offers no advantage over 0.9% sodium chloride injection in maintaining the patency of intermittent intravenous devices.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3402178

Source DB:  PubMed          Journal:  Clin Pharm        ISSN: 0278-2677


  8 in total

1.  Benefit of heparin in peripheral venous and arterial catheters: systematic review and meta-analysis of randomised controlled trials.

Authors:  A G Randolph; D J Cook; C A Gonzales; M Andrew
Journal:  BMJ       Date:  1998-03-28

2.  Necessity of heparin for maintaining peripheral venous catheters: A systematic review and meta-analysis.

Authors:  Tao You; Jianliang Jiang; Jianchang Chen; Weiting Xu; Li Xiang; Yang Jiao
Journal:  Exp Ther Med       Date:  2017-06-28       Impact factor: 2.447

3.  Heparin-binding motifs and biofilm formation by Candida albicans.

Authors:  Julianne V Green; Kris I Orsborn; Minlu Zhang; Queenie K G Tan; Kenneth D Greis; Alexey Porollo; David R Andes; Jason Long Lu; Margaret K Hostetter
Journal:  J Infect Dis       Date:  2013-07-31       Impact factor: 5.226

Review 4.  Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults.

Authors:  Eduardo López-Briz; Vicente Ruiz Garcia; Juan B Cabello; Sylvia Bort-Martí; Rafael Carbonell Sanchis
Journal:  Cochrane Database Syst Rev       Date:  2022-07-18

5.  Taste and/or Odour Disturbances in Pediatric Patients Undergoing IV Flush with Normal Saline Administered by Prefilled Syringe.

Authors:  Steven J Celetti; Régis Vaillancourt; Elena Pascuet; Diane Sharp
Journal:  Can J Hosp Pharm       Date:  2012-09

6.  Heparinized saline versus normal saline for maintaining peripheral venous catheter patency in China: An open-label, randomized controlled study.

Authors:  Lichun Xu; Yan Hu; Xiaojin Huang; Jianguo Fu; Jinhui Zhang
Journal:  J Int Med Res       Date:  2017-01-30       Impact factor: 1.671

7.  Heparin Mimics Extracellular DNA in Binding to Cell Surface-Localized Proteins and Promoting Staphylococcus aureus Biofilm Formation.

Authors:  Surabhi Mishra; Alexander R Horswill
Journal:  mSphere       Date:  2017-06-21       Impact factor: 4.389

Review 8.  Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults.

Authors:  Eduardo López-Briz; Vicente Ruiz Garcia; Juan B Cabello; Sylvia Bort-Martí; Rafael Carbonell Sanchis; Amanda Burls
Journal:  Cochrane Database Syst Rev       Date:  2018-07-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.